LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF

Lakefront Biotherapeutics NV

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026

$29.79−0.11 (-0.37%)

Close on Oct 19, 2026

Community

Notes and questions about Lakefront Biotherapeutics from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Lakefront Biotherapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is LKFT.

Revenue growth303.5% · median 64.0%

Gross margin97.3% · median 83.5%

Operating margin26.5% · median -25.1%

Net margin28.9% · median -51.1%

Advertisement
300 × 250